ALB and cancer: In vitro cytotoxicity assays confirmed that HSA–PLA (SN-38) nanoparticles exhibited significantly lower IC50 values (0.5–194 nM) across multiple cancer cell lines compared to the clinical standard, irinotecan (CPT-11), indicating superior potency under physiological conditions.